

specifically binds to the VEGF-D protein, a probe that is a VEGF-D antibody, classified in Class 435, subclass 7.1.


3. Claims 19-22, drawn to a method of modulating VEGF-D gene expression in a brain cancer cell using oligonucleotide, antisense oligonucleotide, classified in Class 536, subclass 24.5; Class 514, subclass 44.
4. Claims 26-28, drawn to a method of identifying a test compound that modulates expression of VEGF-D gene in a brain cancer cell by detecting VEGF-D nucleic acid marker in the cell, classified in Class 435, subclass 6, and 7.23.
5. Claims 29-32, drawn to a method of identifying a test compound that modulates expression of VEGF-D gene in a brain cancer cell by detecting VEGF-D protein marker in the cell, classified in Class 435, subclass 7.1, and 7.21.
6. Claims 33-43, drawn to a method of inhibiting angiogenesis associated with a brain cancer in a subject by administering a molecule to the central nervous system wherein the molecule is an antibody, classified in Class 424, subclass 130.1.

Applicants hereby elect without traverse Group 2 (claims 9-18). Withdrawal of the outstanding restriction requirement and examination on the merits is respectfully requested.

Respectfully submitted,

AKERMAN SENTERFITT

Dated: March 15, 2004



Gregory A. Nelson, Esq.
Registration No. 30,577
Stanley A. Kim
Registration No. 42,730
222 Lakeview Avenue, Suite 400
P.O. Box 3188
West Palm Beach, FL 33402-3188
Tel: 561-653-5000

{WP172338;1}